Aytu BioPharma (AYTU) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$57.6M

Revenue (quarter)

$16.1M

Revenue growth (year over year)

+6.42%

Gross profit (trailing twelve months)

$36.8M

Gross margin

63.95%

Net income (trailing twelve months)

−$14.3M

Net income (quarter)

−$15,000.00

Net income growth (year over year)

+99.92%

Net margin

−24.76%

Return on equity

−52.55%

EPS (trailing twelve months)

−$1.16

Book value per share

$3.29

P/E (trailing twelve months)

—

Price to book

0.61

Debt to assets

66.41%

Payout ratio

—

Dividend yield

—

Company profile

Aytu BioPharma Inc is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. It has single operating segment. Its product portfolio includes EXXUA, ADHD Portfolio, Pediatric Portfolio, and Other. Majority of revenue comes from ADHD Portfolio. It has presence in United States.

• Is Aytu BioPharma (AYTU) profitable?

  No. Aytu BioPharma reported a net loss of $14.3M over the trailing twelve months.

• How much revenue does Aytu BioPharma (AYTU) make?

  Aytu BioPharma generated $57.6M in revenue over the trailing twelve months, up 6.42% year over year.

• How do I buy stock in Aytu BioPharma (AYTU)?

  AYTU trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.